Oncolytics Biotech Inc. (ONCY)
Nasdaq · Healthcare · Biotechnology
$0.5969−5.40%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $76.1M
- 52-week range
- $0.5801 – $1.39
- 52-week change
- −53.33%
- EPS (trailing)
- −$0.35
- Analyst rating
- 1.8 Buy
- Next earnings
- Nov 16, 2026
Fiscal year to Dec 2025
- Net income
- −$28.8M
- Diluted EPS
- −$0.30
- Free cash flow
- −$20.1M
From the company’s annual report on SEC EDGAR.
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Headquarters: San Diego, United States · 29 employees · oncolyticsbiotech.com